Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.